BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38672574)

  • 1. Programmed Death 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Gene Expression in Peripheral Blood Mononuclear Cells Can Serve as Prognostic Biomarkers for Hepatocellular Carcinoma.
    Lee JA; Choi HG; Eun HS; Bu J; Jang TM; Lee J; Son CY; Kim MS; Rou WS; Kim SH; Lee BS; Kim HN; Lee TH; Jeon HJ
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
    Sun DW; An L; Huang HY; Sun XD; Lv GY
    Clin Transl Oncol; 2021 Jan; 23(1):82-91. PubMed ID: 32462395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of prognostic value and immune infiltration of IAPs family in hepatocellular carcinoma.
    Yang X; Yu X; Nie H; Jiang W; Zhou J; Ou C; He X
    J Cancer; 2023; 14(15):2848-2866. PubMed ID: 37781078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
    Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
    Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
    Liu W; Chai L; Liang J; Lu Z; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma.
    Bao S; Jiang X; Jin S; Tu P; Lu J
    Front Oncol; 2021; 11():694145. PubMed ID: 34249750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Kudo M; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Tsurusaki M; Nishida N
    Liver Cancer; 2024 Feb; 13(1):56-69. PubMed ID: 38344443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
    Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
    Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Apr; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic Analyses Reveal Long Non-Coding RNA in Peripheral Blood Mononuclear Cells as a Novel Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Kunadirek P; Pinjaroen N; Nookaew I; Tangkijvanich P; Chuaypen N
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of long non-coding RNA
    Liao X; Chen J; Luo D; Luo B; Huang W; Xie W
    Pathol Oncol Res; 2022; 28():1610808. PubMed ID: 36685103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.